Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 690-699

  Hsu, Chia Yang ^a,b   Hsia, Cheng Yuan ^a,b   Huang, Yi Hsiang ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Chiou, Yi You ^a,b   Lee, Rheun Chuan ^a,b   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b   Lee, Shou Dong ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Propensity model; Renal insufficiency

Indexed keywords

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE;

EID: 84863374775     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06886.x     Document Type: Article

References (38)

1. Yuen MF, Hou JL, Chutaputti A etal. Hepatocellular carcinoma in the Asia Pacific region. J. Gastroenterol. Hepatol. 2009; 24: 346-53.
2. Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2010; 25: 1217-26.
3. Huo TI, Lin HC, Lee FY etal. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int. 2006; 26: 55-61.
4. Gines P, Schrier RW. Renal failure in cirrhosis. N. Engl. J. Med. 2009; 361: 1279-90.
5. Eckardt KU. Renal failure in liver disease. Intensive Care Med. 1999; 25: 5-14.
6. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am. J. Gastroenterol. 2001; 96: 2206-10.
7. Wiesner R, Edwards E, Freeman R etal. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
8. Hsu CY, Lin HC, Huang YH etal. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig. Liver Dis. 2010; 42: 137-42.
9. Huo TI, Lin HC, Huang YH etal. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006; 107: 141-8.
10. Hsu CY, Huang YH, Chiang JH etal. Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency. J. Clin. Gastroenterol. 2010; 44: e171-7.
11. Huo TI, Huang YH, Wu JC etal. Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. Eur. J. Gastroenterol. Hepatol. 2004; 16: 325-31.
12. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 840-5.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
14. Kudo M, Chung H, Haji S etal. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-405.
15. Hsu CY, Huang YH, Hsia CY etal. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J. Hepatol. 2010; 53: 108-17.
16. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35: 421-30.
17. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin. Liver Dis. 1988; 8: 12-25.
18. Gines P, Angeli P, Lenz K etal. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 2010; 53: 397-417.
19. Gonwa TA, Jennings L, Mai ML etal. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004; 10: 301-9.
20. Lamb EJ, Tomson CR, Roderick PJ. Estimating kidney function in adults using formulae. Ann. Clin. Biochem. 2005; 42: 321-45.
21. The National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39: S1-266.
22. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 693-9.
23. Hsu CY, Hsia CY, Huang YH etal. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010; 116: 3006-14.
24. Pearl J, ed. Understanding propensity scores. Causality: Models, Reasoning, and Inference, 2nd edn. Cambridge: Cambridge University Press, 2009.
25. Mirici-Cappa F, Gramenzi A, Santi V etal. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut 2010; 59: 387-96.
26. Hsu CY, Huang YH, Chiou YY etal. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan Criteria: a propensity score analysis. Liver Transpl. 2011; 17: 556-66.
27. Feinstein AR. Clinical biostatistics. XVI. The process of prognostic stratification. 2. Clin. Pharmacol. Ther. 1972; 13: 609-24.
28. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat. Med. 1997; 16: 965-80.
29. Huo TI, Hsu CY, Huang YH etal. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int. 2010; 30: 198-207.
30. Garcia-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann. Hepatol. 2009; 8: 13-20.
31. Huo TI, Wu JC, Lui WY etal. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am. J. Gastroenterol. 2004; 99: 1479-87.
32. Yeh CN, Lee WC, Chen MF. Hepatic resection for hepatocellular carcinoma in end-stage renal disease patients: two decades of experience at Chang Gung Memorial Hospital. World J. Gastroenterol. 2005; 11: 2067-71.
33. Sawada T, Kita J, Rokkaku K etal. Hepatectomy in patients with nonuremic minimal renal failure. J. Gastrointest. Surg. 2006; 10: 740-5.
34. Huo TI, Huang YH, Wu JC etal. Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. Ann. Oncol. 2004; 15: 775-80.
35. Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives. J. Chin. Med. Assoc. 2005; 68: 155-9.
36. Kondo Y, Yoshida H, Tomizawa Y etal. Percutaneous radiofrequency ablation of hepatocellular carcinoma in 14 patients undergoing regular hemodialysis for end-stage renal disease. Am. J. Roentgenol. 2009; 193: 964-9.
37. Marelli L, Stigliano R, Triantos C etal. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol. 2007; 30: 6-25.
38. Tsai YJ, Hsu CY, Huang YH etal. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol. Int. 2011 PMID 21533669 (in press).